Revier Therapeutics, today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.

The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium.

The Friends of the German Cancer Research Center (DKFZ) support the DKFZ and aim to help strengthen its position in the international arena. With the DKFZ Innovation Award, presented at this year’s annual reception, the association honors Helmut Salih, a researcher whose innovative work bridges the gap between immunological research and patient care.

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

The European Union is funding the PALACROS project with nearly €10 million under its “Horizon Europe” research programme. Researchers from Heidelberg University Hospital and Heidelberg University are helping shape the European PALACROS consortium, developing new standards for the treatment of locally advanced pancreatic cancer.

Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.

A team led by researchers from the German Cancer Research Center and the HI-STEM* Stem Cell Institute has discovered a new approach to treating advanced colorectal cancer. The study identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells.

In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time.

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab.

Not only actual chronological age, but also individual aging at the molecular level is a key factor in the development of cancer. This was discovered by scientists at the DKFZ and the Saarland Cancer Registry. If the so-called “epigenetic clocks” indicate accelerated biological aging, the likelihood of a cancer diagnosis increases. This finding could help identify at-risk groups and make early detection screenings more targeted

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.

Proof-of-concept study of organoid technology - 26/03/2026

Can organoids improve the treatment of pancreatic cancer?

A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.

The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care.

An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins.

New findings indicate that a shingles vaccination could not only reduce the risk of cognitive impairment and dementia, but also reduce disease progression among those living with dementia.

Alithea Biotechnology GmbH - 12/02/2026

Intelligent immunotherapy – safety ensured

Immunological cell fingerprints are Alithea Bio’s core expertise. The Freiburg-based company combines advanced molecular biology with cutting-edge IT and operates one of the world’s largest immunopeptidomics databases. Alithea Bio leverages this integrated platform to offer both contract research services and software-as-a-service solutions to develop safer and more precise personalised immunotherapies more quickly.

CorTec GmbH, a pioneer in active implantable medical technologies, announced the successful second implantation of its proprietary Brain-Computer Interface system in a clinical trial. The implantation follows neurological gains observed in the study’s first participant. This represents another key milestone to evaluate CorTec’s fully implantable closed-loop BCI platform for therapeutic applications.